Millennium Management
OCUL icon

Millennium Management’s Ocular Therapeutix OCUL Stock Holding History

Millennium Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-70,000
Closed -$850K – 6175
2025
Q4 		$850K Buy
+70,000
New +$850K ﹤0.01% 4594

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management's OCUL Position: Q1 2026 in Review

Millennium Management reduced its Ocular Therapeutix (OCUL) stake by 99% in Q1 2026, selling an estimated $30.2M and leaving 34,006 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #5023.

Millennium Management first reported a position in OCUL in Q3 2014 and has held it in 31 quarters since. The position peaked at $45.1M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Millennium Management held 34,006 shares of Ocular Therapeutix worth $288K as of Q1 2026.
  • Millennium Management sold 3,173,875 Ocular Therapeutix shares in Q1 2026, an estimated $30.2M.
  • Ocular Therapeutix made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5023 holding.
  • Millennium Management first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 31 quarters since.
  • Millennium Management's Ocular Therapeutix position peaked at $45.1M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.